JORGE E CORTES to STAT3 Transcription Factor
This is a "connection" page, showing publications JORGE E CORTES has written about STAT3 Transcription Factor.
Connection Strength
0.089
-
Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome. Curr Hematol Rep. 2004 May; 3(3):157-8.
Score: 0.036
-
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.
Score: 0.016
-
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27.
Score: 0.014
-
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73.
Score: 0.012
-
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007 Jan 01; 109(1):315-22.
Score: 0.011